FDA accepts Takeda’s NDA resubmission for eosinophilic esophagitis therapy

21 Sep 2023
www.pharmaceutical-technology.com
NDA
FDA accepts Takeda’s NDA resubmission for eosinophilic esophagitis therapy
Preview
Source: Pharmaceutical Technology
The resubmission aims to respond to the FDA’s prior feedback on Takeda’s original new drug application submission. Credit: Tada Images/Shutterstock.com.
The US Food and Drug Administration (FDA) has accepted Takeda’s new drug application (NDA) resubmission for TAK-721 (budesonide oral suspension) for the short-term treatment of eosinophilic esophagitis (EoE), for review.
EoE is a chronic, immune-mediated, inflammatory disease localised in the oesophagus.
Recommended Reports
FDA accepts Takeda’s NDA resubmission for eosinophilic esophagitis therapy
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - (Aspirin + Dimethyl Fumarate) in Relapsing Remitting Multiple Sclerosis (RRMS) GlobalData
FDA accepts Takeda’s NDA resubmission for eosinophilic esophagitis therapy
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Mipasetamab Uzoptirine in Liposarcoma GlobalData
View allCompanies IntelligenceTakeda OyView all
TAK-721, a new mucoadherent topically active oral viscous formulation of budesonide, is an investigational treatment for EoE. It is intended to treat the localised oesophageal inflammation caused by EoE.
Takeda’s resubmission aims to respond to the FDA’s prior feedback on its original NDA submission.
Meanwhile, the company is anticipating the FDA decision in the first half of next year.
Takeda US Medical for Gastroenterology head and vice-president Vijay Yajnik said: “Over the past several months, we have reanalysed the TAK-721 clinical data and pursued a dialogue with the FDA because we recognise EoE patients need additional therapeutic options.
“As a result of that constructive discussion, we have resubmitted our NDA with a revised proposed indication, for short-term treatment of EoE.”
In December 2021, Takeda received a complete response letter from the FDA in relation to its NDA for TAK-721 intended for the treatment of EoE.
The FDA concluded its review of the TAK-721 NDA and found it unsuitable for approval in its current form.
Furthermore, the FDA suggested conducting an additional clinical study to address its feedback.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.